Train Babcock Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
$328K Sell
9,566
-3,514
-27% -$120K 0.14% 79
2017
Q3
$443K Hold
13,080
0.25% 57
2017
Q2
$416K Hold
13,080
0.18% 82
2017
Q1
$424K Sell
13,080
-2,899
-18% -$91.4K 0.19% 80
2016
Q4
$492K Sell
15,979
-1,343
-8% -$41K 0.2% 82
2016
Q3
$556K Buy
17,322
+1,264
+8% +$42.3K 0.22% 76
2016
Q2
$537K Sell
16,058
-948
-6% -$30.3K 0.21% 79
2016
Q1
$478K Sell
17,006
-774
-4% -$22.1K 0.19% 82
2015
Q4
$544K Buy
17,780
+510
+3% +$16K 0.21% 81
2015
Q3
$515K Sell
17,270
-2,066
-11% -$66.2K 0.18% 87
2015
Q2
$615K Sell
19,336
-948
-5% -$30.9K 0.19% 85
2015
Q1
$669K Hold
20,284
0.21% 81
2014
Q4
$600K Buy
20,284
+1,175
+6% +$33.7K 0.19% 85
2014
Q3
$536K Sell
19,109
-3,821
-17% -$107K 0.18% 89
2014
Q2
$646K Sell
22,930
-179
-0.8% -$5.1K 0.21% 83
2014
Q1
$704K Hold
23,109
0.23% 81
2013
Q4
$672K Sell
23,109
-1,534
-6% -$44.6K 0.23% 77
2013
Q3
$672K Buy
24,643
+317
+1% +$8.63K 0.25% 73
2013
Q2
$646K Buy
+24,326
New +$672K 0.24% 70

Other funds holding PFE

Train Babcock Advisors's PFE Position: Q4 2017 in Review

Train Babcock Advisors reduced its Pfizer (PFE) stake by 27% in Q4 2017, selling an estimated $120K and leaving 9,566 shares worth $328K. The position accounts for 0.14% of the portfolio, ranked #79.

Train Babcock Advisors first reported a position in PFE in Q2 2013 and has held it in 19 quarters since. The position peaked at $704K in Q1 2014. 2,244 funds tracked by Wall St. Rank hold PFE as of Q4 2017.

  • Train Babcock Advisors held 9,566 shares of Pfizer worth $328K as of Q4 2017.
  • Train Babcock Advisors sold 3,514 Pfizer shares in Q4 2017, an estimated $120K.
  • Pfizer made up 0.14% of Train Babcock Advisors's portfolio in Q4 2017, its #79 holding.
  • Train Babcock Advisors first reported a position in Pfizer in Q2 2013 and has held it in 19 quarters since.
  • Train Babcock Advisors's Pfizer position peaked at $704K in Q1 2014.
  • 2,244 funds tracked by Wall St. Rank held Pfizer as of Q4 2017.

Based on Train Babcock Advisors's 13F filing for Q4 2017, filed 10 Jan 2018.